Received Jul 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Early 2nd dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 36-year-old male patient who received HAV (Havrix) for prophylaxis. Concomitant products included Hepatitis a vaccine inact (Havrix). On 23-JUN-2025, the patient received the 2nd dose of Havrix. On 23-JUN-2025, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: Early 2nd dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-JUN-2025 The reporter calling because a patient was given a vaccine (Havrix) too early. The vaccine administration facility was the same as primary reporter. During the call, the healthcare professional informed that this was about Havrix. The patient received the 1st dose on 21st May 2025 and then the 2nd dose on 23rd June 2025 which led to shortening of vaccination schedule.
Havrix